No area of medicine has been the subject of more hype, misinformation, and confusion than developing web sites for physician practices. Hundreds and perhaps thousands of our urologic colleagues have created web sites only to be left with a bad taste about the time, money, and effort spent on a medium that does not appear to generate more patients or improve practice efficiency.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Drug extends survival in prostate cancer with genetic mutations
December 8th 2023“Our analysis suggests that there is superior clinical benefit with olaparib versus control both in patients who had and had not received previous taxane treatment,” said Maha Hussain, MD, Robert H. Lurie Comprehensive Cancer Center of Northwestern University.